In this study, we established an in vitro uric acid uptake model for the preliminary screening of novel URAT1 inhibitors, and two hyperuricemic mouse models with different pathophysiological characteristics to validate the therapeutic effect on hyperuricemia. This evidence concerns the gene SLC22A12 and hyperuricemia.